Proteasome Inhibitors Induce Cell Death in T-Cell Prolymphocytic Leukemia
Author Information
Author(s): Gasparini Vanessa Rebecca, Rampazzo Elisa, Barilà Gregorio, Buratin Alessia, Buson Elena, Calabretto Giulia, Vicenzetto Cristina, Orsi Silvia, Tonini Alessia, Teramo Antonella, Trentin Livio, Facco Monica, Semenzato Gianpietro, Bortoluzzi Stefania, Zambello Renato
Primary Institution: University of Padova
Hypothesis
Proteasome inhibitors can reverse the T-PLL phenotype and induce apoptosis in leukemic cells.
Conclusion
Proteasome inhibitors Bortezomib and Carfilzomib significantly increase apoptosis in T-PLL cells.
Supporting Evidence
- Proteasome inhibitors were identified as effective through drug repurposing analysis.
- Bortezomib and Carfilzomib treatment led to significant apoptosis in T-PLL cells.
- Results were validated in both primary T-PLL samples and the SUP-T11 cell line.
- Apoptosis was confirmed through flow cytometry and Western blot analysis.
Takeaway
This study found that certain drugs can help kill cancer cells in a rare type of leukemia called T-PLL, which is usually hard to treat.
Methodology
The study involved drug repurposing analysis and treatment of ex vivo T-PLL cells with proteasome inhibitors, followed by evaluation of apoptosis.
Limitations
The rarity of T-PLL limits the sample size and generalizability of the findings.
Participant Demographics
Median age at diagnosis was 72 years, with no gender differences.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website